Latest Updates

NEWS PROVIDED BY Juniper Biologics  Apr 21, 2024, 21:00 ET SINGAPORE, April 18, 2024 /PRNewswire/ — Juniper Biologics (“Juniper“), a global science-led pharmaceutical company dedicated to advancing treatments in specialised therapy areas, has been named “Pharmaceutical Company of the Year” by the Corporate LiveWire Global Awards for the year 2023-2024. The Corporate LiveWire Global Awards spotlight the outstanding achievements … Read more

SINGAPORE, 25 MARCH 2024 – Juniper Biologics (“Juniper”), Singapore-based science-led pharmaceutical company focused on researching, developing, and commercializing novel therapies, celebrates another milestone as it received the award for Best Novel Therapy R&D and Commercialization Company at the APAC Insider Singapore Business Awards 2024. The APAC Insider Singapore Business Awards serves to spotlight companies and … Read more

2024-01-08 09:00 SINGAPORE, Jan. 8, 2024 /PRNewswire/ — Juniper Biologics (“Juniper“), a global science-led pharmaceutical company headquartered in Singapore, proudly announces its latest achievement, winning the award for Molecular Science & Technology Acquisition of the Year at Acquisition International’s M&A Awards 2023. This recognition highlights Juniper’s unwavering commitment to advancing treatments in oncology-supportive care and its … Read more

https://www.prnewswire.co.uk/news-releases/juniper-therapeutics-acquires-exclusive-rights-for-sar-registration-for-anti-viral-covid-19-drug-from-ping-an-shionogi-hong-kong-for-singapore-302021003.html?tc=eml_cleartime

SINGAPORE, 23 OCTOBER 2023 – Juniper Biologics, a global science-led pharmaceutical company headquartered in Singapore, has been honored with the prestigious title of the “Most Innovative Oncology Pharmaceutical Company 2023” by the Global Health & Pharma (GHP) Healthcare and Pharmaceutical Awards. This recognition underscores Juniper Biologics’ commitment to advancing healthcare by delivering groundbreaking therapies in … Read more

SINGAPORE, JANUARY 12, 2023: Singapore-headquartered Juniper Biologics Pte Ltd, a science-led healthcare company focused on commercialising novel therapies, has been granted distribution rights for Caris Life Sciences® (Caris)’ molecular profiling services in South East Asia. Caris is the leading molecular science and technology company actively developing and delivering innovative solutions to revolutionize healthcare. The company’s … Read more

Lugano, Switzerland, September 1, 2022 – Helsinn Group (“Helsinn”), a fully integrated, global biopharma company with a diversified pipeline of innovative oncology assets and strong track-record of commercial execution, and Juniper Biologics Pte Ltd, a science-led healthcare company focused on researching, developing and commercializing novel therapies, announced today the signing of an exclusive distribution license and … Read more

$600 million USD acquisition will see Juniper Biologics offer the world’s first cell-mediated gene therapy to an estimated 300 million patients in Asia Pacific, Middle East and Africa.

Helsinn Healthcare SA announced the signing of exclusive distribution, license and supply agreements for Aloxi®, Onicit®, Paloxi®, Akynzeo® (IV and oral formulations) and anamorelin (INN).